Mobilized CLL cells obtained from the PB of patients after treatment with the BTK-inhibitor ibrutinib showed reduced MCL-1 and BCL-XL levels and enhanced BIM levels compared to pre-ibrutinib samples [10, 49]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.